Menu
Currency
GWAS Study

Genome-wide association study of anti-Müllerian hormone levels in pre-menopausal women of late reproductive age and relationship with genetic determinants of reproductive lifespan.

Ruth KS, Soares ALG, Borges MC et al.

30649302 PubMed ID
GWAS Study Type
3344 Participants
88 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

RK
Ruth KS
SA
Soares ALG
BM
Borges MC
EA
Eliassen AH
HS
Hankinson SE
JM
Jones ME
KP
Kraft P
NH
Nichols HB
SD
Sandler DP
SM
Schoemaker MJ
TJ
Taylor JA
ZA
Zeleniuch-Jacquotte A
LD
Lawlor DA
SA
Swerdlow AJ
MA
Murray A
Chapter II

Abstract

Summary of the research findings

Anti-Müllerian hormone (AMH) is required for sexual differentiation in the fetus, and in adult females AMH is produced by growing ovarian follicles. Consequently, AMH levels are correlated with ovarian reserve, declining towards menopause when the oocyte pool is exhausted. A previous genome-wide association study identified three genetic variants in and around the AMH gene that explained 25% of variation in AMH levels in adolescent males but did not identify any genetic associations reaching genome-wide significance in adolescent females. To explore the role of genetic variation in determining AMH levels in women of late reproductive age, we carried out a genome-wide meta-analysis in 3344 pre-menopausal women from five cohorts (median age 44-48 years at blood draw). A single genetic variant, rs16991615, previously associated with age at menopause, reached genome-wide significance at P = 3.48 × 10-10, with a per allele difference in age-adjusted inverse normal AMH of 0.26 standard deviations (SD) (95% confidence interval (CI) [0.18,0.34]). We investigated whether genetic determinants of female reproductive lifespan were more generally associated with pre-menopausal AMH levels. Genetically-predicted age at menarche had no robust association but genetically-predicted age at menopause was associated with lower AMH levels by 0.18 SD (95% CI [0.14,0.21]) in age-adjusted inverse normal AMH per one-year earlier age at menopause. Our findings provide genetic support for the well-established use of AMH as a marker of ovarian reserve.

3,344 European ancestry women

Chapter III

Study Statistics

Key metrics and study information

3344
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
U.S., U.K., Puerto Rico
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.